Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Novel therapeutics for chemotherapy-resistant acute myeloid leukaemia
Autore:
Frankel, AE; Schuster, MW; Jurcic, JG;
Indirizzi:
Wake Forest Univ, Sch Med, Winston Salem, NC 27157 USA Wake Forest Univ Winston Salem NC USA 27157 , Winston Salem, NC 27157 USA Cornell Univ, Med Ctr, New York, NY 10021 USA Cornell Univ New York NY USA 10021 Univ, Med Ctr, New York, NY 10021 USA Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA Mem Sloan Kettering Canc Ctr New York NY USA 10021 New York, NY 10021 USA
Titolo Testata:
BIODRUGS
fascicolo: 1, volume: 15, anno: 2001,
pagine: 55 - 71
SICI:
1173-8804(2001)15:1<55:NTFCAM>2.0.ZU;2-4
Fonte:
ISI
Lingua:
ENG
Soggetto:
ACUTE MYELOGENOUS LEUKEMIA; COLONY-STIMULATING FACTOR; MONOCLONAL-ANTIBODY HUM195; ACUTE PROMYELOCYTIC LEUKEMIA; FACTOR FUSION PROTEIN; NON-HODGKINS-LYMPHOMA; PHASE-I TRIAL; DIPHTHERIA-TOXIN; HUMANIZED ANTI-CD33; 1-BETA-D-ARABINOFURANOSYLCYTOSINE-INDUCED APOPTOSIS;
Tipo documento:
Review
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Citazioni:
74
Recensione:
Indirizzi per estratti:
Indirizzo: Frankel, AE Wake Forest Univ, Sch Med, Winston Salem, NC 27157 USA Wake Forest Univ Winston Salem NC USA 27157 lem, NC 27157 USA
Citazione:
A.E. Frankel et al., "Novel therapeutics for chemotherapy-resistant acute myeloid leukaemia", BIODRUGS, 15(1), 2001, pp. 55-71

Abstract

Patients with chemotherapy-resistant acute myeloid leukaemia are rarely cured by non-allogeneic transplant therapies. Multiple new investigational agents have become available for treatment of these patients and there are few tools to permit rational drug and clinical trial selection. In this review, we describe the chemical and biological properties of some of these agents and some of their initial clinical activity to date. The selected agentsreact with either cell surface molecules or signal pathway intermediates and include antibody and antibody conjugates to CD33 and CD45, a fusion protein directed to the granulocyte-macrophage colony-stimulating factor receptor, an anti-sense oligonucleotide to Bc12, a farnesyl transferase inhibitor, and a protein kinase C agonist/inhibitor. The challenge for the next decade will be how to select patients for particular molecularly targeted therapeutics and how to combine these agents.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 11/07/20 alle ore 21:06:17